Greenwich LifeSciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| 2024 | 2023 | |
|---|---|---|
| Revenue | $— | $— |
| Operating expenses | ||
| Research and development | 12,952,029 | 7,698,622 |
| General and administrative | 3,059,788 | 1,629,244 |
| Total operating expenses | 16,011,817 | 9,327,866 |
| Loss from operations | (16,011,817) | (9,327,866) |
| Interest income | 223,008 | 436,063 |
| Net loss | $(15,788,809) | $(8,891,803) |
| Per share information: | ||
| Net loss per common share, basic and diluted | $(1.21) | $(0.69) |
| Weighted average common shares outstanding, basic and diluted | 13,014,585 | 12,848,165 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.